NCT01395992View on ClinicalTrials.gov

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Bipolar I Disorder
Interventions
DRUG

asenapine

asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days

DRUG

asenapine

asenapine 10 mg tablet, SL BID for 182 days

Trial Locations (1)

78754

Forest Investigative Site 1000, Austin

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT01395992 - Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692) | Biotech Hunter | Biotech Hunter